Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of 18F-Fluorocholine PET/CT in MEN1 Syndrome

被引：6

作者：

Arora S. ^{[1
]}

Damle N.A. ^{[1
]}

Passah A. ^{[1
]}

Yadav M.P. ^{[1
]}

Ballal S. ^{[1
]}

Aggarwal V. ^{[2
]}

Gupta Y. ^{[3
]}

Kumar P. ^{[1
]}

Tripathi M. ^{[1
]}

Bal C. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi

[2] Department of Endocrine Surgery, Maharaja Agrasen Hospital, New Delhi

[3] Department of Endocrine, All India Institute of Medical Sciences, New Delhi

来源：

Nuclear Medicine and Molecular Imaging | 2018年 / 52卷 / 3期

关键词：

!sup]177[!/sup]Lu-DOTATATE therapy; !sup]18[!/sup]F-Fluorocholine PET/CT; Gastrinoma; Hyperparathyroidism; MEN1;

D O I：

10.1007/s13139-018-0520-2

中图分类号：

学科分类号：

摘要：

Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by combined occurrence of tumors of endocrine glands including the parathyroid, the pancreatic islet cells, and the anterior pituitary gland. Parathyroid involvement is the most common manifestation and usually the first clinical involvement in MEN1 syndrome, followed by gastroentero-pancreatic neuroendocrine tumors (NETs). Here we present a case where the patient initially presented with metastatic gastric NET and a single parathyroid adenoma was detected incidentally on 68Ga-DOTANOC PET/CT done as part of post 177Lu-DOTATATE therapy (PRRT) follow-up. Further 18F-fluorocholine PET/CT showed four adenomas for which the patient subsequently underwent subtotal parathyroidectomy. © 2018, Korean Society of Nuclear Medicine.

引用

页码：238 / 242

页数：4

共 18 条

[1] Thakker R.V., Multiple endocrine neoplasia type 1, Indian J Endocrinol Metab, 16, pp. 272-274, (2012)
[2] Lemos M.C., Thakker R.V., Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene, Hum Mutat, 29, pp. 22-32, (2008)
[3] Machens A., Schaaf L., Karges W., Frank-Raue K., Bartsch D.K., Rothmund M., Et al., Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers, Clin Endocrinol, 67, pp. 613-622, (2007)
[4] Lips C.J., Dreijerink K.M., Hoppener J.W., Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype-phenotype correlation, Clinics, 67, pp. 49-56, (2012)
[5] Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Et al., Guidelines for diagnosis and therapy of MEN type 1 and type 2, J Clin Endocrinol Metab, 86, pp. 5658-5671, (2001)
[6] Marx S., Spiegel A.M., Skarulis M.C., Doppman J.L., Collins F.S., Liotta L.A., Multiple endocrine neoplasia type 1: clinical and genetic topics, Ann Intern Med, 129, pp. 484-494, (1998)
[7] Giusti F., Tonelli F., Brandi M.L., Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?, Clinics, 67, pp. 141-144, (2012)
[8] Marx S.J., Menczel J., Campbell G., Et al., Heterogeneous size of the parathyroid glands in familial multiple endocrine neoplasia type 1, Clin Endocrinol, 35, pp. 521-526, (1991)
[9] Gouveia S., Rodrigues D., Barros L., Ribeiro C., Albuquerque A., Costa G., Carvalheiro M., Persistent primary hyperparathyroidism: an uncommon location for an ectopic gland-case report and review, Arq Bras Endocrinol Metabol, 56, pp. 393-403, (2012)
[10] Schreinemakers J.M., Pieterman C.R., Scholten A., Vriens M.R., Valk G.D., Rinkes I.H., The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review, World J Surg, 35, pp. 1993-2005, (2011)

← 1 2 →